Skip to Content

Clinical Trials

Many of our physicians are participating in clinical studies or serving as principal investigators. These studies research questions with significant implications for patients. Patients who participate in clinical trials receive access to the current standard of care, as well as the potential to be treated with a new innovative therapy even before it becomes widely available. Other studies seek to improve quality of life for patients.

Odyssey Outcomes

A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effect of SAR236553/REGN727 on the occurrence of cardiovascular events in patients who have recently experienced acute coronary syndrome. Learn more about the study.

If you would like to learn more about this trial, please follow the link below or contact Justine Garceau,MA,CCRC at 425-635-6082 or or Tina Fortney at

Mild and Rapidly Improving Stroke Study (MaRISS)

Mild and Rapidly Improving Stroke Study (MaRISS) is a joint endeavor between the Americal Heart Association, Americal Stroke Association and the University of Miami. The MaRISS study was designed to help address a critical knowledge gap: What are the long-term outcomes of patients with a diagnosis of mild stroke? What do they experience after discharge? This will be the first ever large-scale prospective study to evaluate the long-term outcomes for these patients in a standardized manner.

If you would like to learn more about this trial, please contact Tina Fortney, RN, CCRC at 425-688-5407 or

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Emoblic Stroke of Undetermined Source (RE-SPECT ESUS)

You are being asked to participate in this research study because you have a condition called embolic stroke of undetermined source (ESUS), a type of ischemic stroke. An ischemic stroke occurs when an artery supplying blood to the brain becomes blocked. For most ischemic strokes, tests can be done to determine the cause of the blockage (for example, a blood clot). However, there is one type of ischemic stroke, where, despite testing, the origin of the blood clot causing the blockage is not identifiable. This condition has recently been named "embolic stroke of undetermined source" (ESUS). Subjects who experience a stroke due to a clot are at risk for another stroke. The majority of these subjects require lifelong treatment with a blood thinning medication to reduce the risk of another stroke.

The purpose of this study is to test the safety and effectiveness of the anticoagulant dabigatran etexilate taken twice daily compared to aspirin [acetylsalicylic acid (Acetylsalicylsaure 100 mg HEXAL®)] which is taken once daily for the prevention of stroke recurrence in subjects with ESUS.

If you would like to learn more about this trial, please contact Tina Fortney, RN, CCRC at 425-688-5407 or

Clinical Trial Categories

Potential Benefits

  • Possibility of early access to innovative therapies that may be better than current treatment options.
  • Study-related healthcare provided by a team of experts, including top physicians and researchers, along with nurses, statisticians and social workers.
  • Enhanced patient monitoring and individualized care.
  • Increased understanding of the disease and its treatment.

Potential Risks/Disadvantages

  • Possibility of unknown side effects.
  • New drug/treatment may be ineffective or less effective than current options.
  • Greater time commitment to treatment.

Who qualifies?

Not everyone with a specific disease or condition is eligible. Type and extent of disease, age and health status can determine your eligibility. But if early results of an experimental treatment are encouraging, eligibility is usually broadened.

If you are interested in any of the listed protocols at Overlake, you may contact Tina Fortney, BSN certified clinical research supervisor, at 425-688-5407.

Additional Resources